Our community
Our inspirational customers are accelerating proteomics research at an ever faster pace, and love to share their successes and insights with each other and with us. This is what we call the “Olink community”!
Heart to heart – Faiez Zannad in his own words
Customer stories
Professor Faiez Zannad, one of the world’s foremost researchers in the area of heart failure, talks about his work, and the importance of protein biomarkers in his field
Longitudinal COVID-19 proteomics study from MGH
COVID-19, Customer stories, Disease areas
Olink is immensely proud of our contribution to one of the largest longitudinal COVID-19 studies together with the prestigious Massachusetts General Hospital (MGH).
A rare but severe complication in children with COVID-19
COVID-19, Customer stories, Disease areas
A study by Petter Brodin's group at the Karolinska Institute sheds new light on Inflammatory Syndrome in Children (MIS-C). The results were published in Cell.
Protein biomarkers of COVID-19 pathophysiology (Radboud UMC)
COVID-19, Customer stories, Disease areas
A team from the Netherlands used targeted proteomics to find inflammatory and other biomarkers that characterize COVID-19 and the severity of the disease.
Immune system development in children – Petter Brodin
Customer stories, Understanding human biology
Petter Brodin talks about his landmark study (Olin et al, 2018), published in Cell, "Stereotypic immune system development in newborn children"
SCALLOP publication in Nature Metabolism
Customer stories, Drug discovery and development
SCALLOP consortium study in Nature Metabolism identifies protein quantitative trait loci (pQTL) for 90 cardiovascular proteins in over 30,000 individuals.
Systems-level immunomonitoring of severe COVID-19
COVID-19, Customer stories, Disease areas
A longitudinal, systems-level approach characterizes cellular and protein immune responses in severe COVID-19, and during the recovery phase following severe disease.
View from the inside – SCALLOP pQTL CVD I study
Customer stories, Drug discovery and development
SCALLOP founder, Anders Mälarstig, talks about the consortium’s first major combined study, which was recently made available on bioRxiv
Customer stories
In a recent editorial article with SelectScience, Dr. Magis describes how his team is using longitudinal proteomics measurements to identify early signals and transition ...
Customer consortia
COLLIBRI is a consortium that aims to accelerate progress in the field of inflammatory bowel disease through the use of protein biomarkers.
The aim of the CORAL consortium is to identify novel biomarkers and biological mechanisms for neurological diseases that are developed into biomarkers for diagnostic, prognostic, disease monitoring, and/or treatment response evaluation.
The SCALLOP consortium is a collaborative framework for the discovery and follow-up of genetic associations with proteins on the Olink Proteomics platform.
Customer recommendations
